SLXP Salix Pharmaceuticals Ltd.

304

52-Wk High	$0.00
52-Wk Low	$0.00

Fundamentals

RedHill Biopharma sees growing revenues and significant progress in its pipeline that's more than a COVID-19 playProactiveinvestors USA & Canada • almost 3 years ago

--- - With the worlds focus currently on COVID-19, you might be forgiven for thinking that RedHill BiopharmaLtd's (NASDAQ:RDHL) (FRA:2RH) development of a promising Covid treatment is the only thing that matters for this interesting company. But this would be far from the truth as the specialty ...

Share to Feed

Financial Comparison: Newron Pharmaceuticals (OTCMKTS:NWPHF) & Progenics Pharmaceuticals (OTCMKTS:PGNX)Zolmax • over 3 years ago

--- - Newron Pharmaceuticals (OTCMKTS:NWPHF) and Progenics Pharmaceuticals (NASDAQ:PGNX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst ...

Progenics Pharmaceuticals (NASDAQ:PGNX) & DelMar Pharmaceuticals (NASDAQ:DMPI) Head to Head AnalysisZolmax • over 3 years ago

--- - Progenics Pharmaceuticals (NASDAQ:PGNX) and DelMar Pharmaceuticals (NASDAQ:DMPI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, ...

Raleigh's RedHill brings back drug candidate from SalixBizjournals.com - Health Care News • almost 4 years ago

--- - 'As a Raleigh drugmaker moves into commercial mode for its newly approved drug, it has announced the termination of an exclusive license for one of its other drug candidates. Redhill Biopharma (Nasdaq: RDHL) - an Israel-based company that calls Raleigh home to its U.S.'

Salix grabs ex-Asia rights to Mitsubishi Tanabe autoimmune drugFierceBiotech.com - Biotech • over 4 years ago

--- - Salix Pharmaceuticals has bagged the ex-Asia rights to Mitsubishi Tanabe's late-phase autoimmune drug, amiselimod. The Bausch Health subsidiary plans to trial the S1P receptor functional antagonist in ulcerative colitis. Amiselimod is designed to inhibit the receptor function of the lymphocyte S1P receptor and thereby keep lymphocytes sequestered in lymph nodes.

Salix grabs ex-Asia rights to Mitsubishi Tanabe autoimmune drugFierceBiotech.com - Biotech • over 4 years ago